Submissions

Driving policy for a stronger life sciences future.

AusBiotech actively contributes to national policy discussions that shape the future of Australia’s biotechnology, medical technology, and digital health sectors.

Our submissions represent the collective voice of the life sciences community, providing evidence-based insights and recommendations to government, regulators, and industry bodies.

2026

AusBiotech submission; 2026-27 Pre-Budget Submission; Federal Treasury
AusBiotech and MTPConnect joint-submission; 2026-27 Pre-Budget Submission - Australia-UK BioBridge; Federal Treasury
AusBiotech and industry partners joint-submission; AusBiotech and industry partners 2026-27 TGA Public Good Funding; Federal Treasury

2025

AusBiotech submission; Possible association to Horizon Europe: Request for information; Department of Industry, Science and Resources
AusBiotech submission; Draft National Health and Medical Research Strategy consultation; Department of Health, Disability and Ageing
AusBiotech submission; AusBiotech response to consultation on Issues Papers; Department of Industry, Science and Resources
AusBiotech submission; AusBiotech Submission to the Community Affairs Legislation Committee; Community Affairs Legislation Committee
AusBiotech and Medicines Australia joint-submission; AusBiotech and Medicines Australia submission to Economic Reform Roundtable; Federal Treasury
AusBiotech submission; AusBiotech Submission to Strategic Examination of R&D; Department of Industry, Science and Resources;
AusBiotech and MTPConnect joint-submission; Pre-Budget Submission 2025-26; Federal Treasury
AusBiotech and Medicines Australia joint-submission; Pre-Budget Submission 2025-26 – Australian Life Sciences Council; Federal Treasury
AusBiotech submission; Pre-Budget Submission 2025-26: Cell and Gene Catalyst; Federal Treasury
AusBiotech, Medical Technology Association of Australia, and Medicines Australia joint-submission; Pre-Budget Submission 2025-26 – National One Stop Shop; Federal Treasury

2024

AusBiotech submission; AusBiotech submission in response to the NSW Innovation Blueprint – Discussion Paper; Investment NSW
AusBiotech submission; Cell & Gene Catalyst submission in response to the Health Technology Assessment Policy and Methods Review - Consultation 2; Department of Health and Aged Care
AusBiotech submission; AusBiotech submission in response to the TGA fees and charges proposal 2024-25 consultation paper; Therapeutic Goods Administration
AusBiotech submission; Pre 2024-25 Federal Budget Submission - The Research & Development Taskforce's National One Stop Shop; Federal Treasury

2023

AusBiotech submission; Australia's Cell & Gene Catalyst's response to the Unleashing the Potential of our Healthcare Workforce – Scope of practice review; Department of Health and Aged Care
AusBiotech submission; Response to the Understanding our RNA potential: discussion paper; Department of Industry, Science and Resources
AusBiotech submission; Response to Draft guidance on requirements for Class 4 in-house IVDs used for screening faecal microbiota transplant (FMT) donors; Therapeutic Goods Administration
AusBiotech submission; Response to the Prostheses List Reforms Consultation Paper 7 - Proposed measures for compliance, assurance and information sharing; Department of Health
AusBiotech submission; Response to the Industry Growth Program; Department of Industry, Science and Resources
AusBiotech submission; Response to Improving alignment and coordination between the Medical Research Future Fund and NHMRC’s Medical Research Endowment Account; Department of Health and Aged Care
AusBiotech submission; Response to the TGA Fees and Charges Proposal 2023-2024 consultation paper; Therapeutic Goods Administration;
AusBiotech submission; Response to draft guidance for therapeutic goods advertising and ASX announcements; Therapeutic Goods Administration;
AusBiotech submission; Response to the National Reconstruction Fund consultation paper; Department of Industry, Science and Resources
AusBiotech and industry partners joint-submission; Securing sustainable funding for the Therapeutic Goods Administration; Federal Treasury
AusBiotech submission; Response to the 'TGA Learn' consultation; Therapeutic Goods Administration

2022

AusBiotech, Medical Technology Association of Australia, and Medicines Australia joint-submission; Submission to the TGA's proposed regulatory changes for clinical trials for medical devices; Therapeutic Goods Administration
AusBiotech submission; Response to the TGA's Fees and charges 2022 - 2023 proposal; Therapeutic Goods Administration
AusBiotech submission; Response to the Prostheses List Reforms - Consultation Paper No. 3 - A modernised fit-for-purpose listing process; Department of Health
AusBiotech submission; Response to the Draft Industry Research and Development (R&D Tax Incentive on clinical trials, Phase 0, I, II, III for an unapproved therapeutic good) Determination 2021; Department of Industry, Science, Energy and Resources

Where life science leaders thrive

Submissions

Driving policy for a stronger life sciences future.

We’ll keep you up to date with the latest